Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients
暂无分享,去创建一个
T. Choueiri | G. Casey | N. Nowak | M. Accavitti-Loper | S. Sizemore | R. Tubbs | D. Welch | J. Crowe | D. Hicks | G. Budd | A. Dawson | S. Tarr | B. Yoder | D. Gaile | A. Frost | M. Cicek | S. Short | Nichole L Prescott | Nichole L. Prescott
[1] W. Gradishar. Estrogen Receptor-Positive, Progesterone Receptor-Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance , 2006 .
[2] M. Cronin,et al. Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes , 2005, Clinical Cancer Research.
[3] D. Slamon,et al. Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways. , 2005, Journal of the National Cancer Institute.
[4] M. Duffy,et al. Expression of the Breast Cancer Metastasis Suppressor Gene, BRMS1, in Human Breast Carcinoma: Lack of Correlation with Metastasis to Axillary Lymph Nodes , 2005, Tumor Biology.
[5] Kristine Broglio,et al. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. , 2005, Cancer.
[6] E. van Limbergen,et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer , 2005, Journal of Clinical Pathology.
[7] G. Casey,et al. Breast Cancer Metastasis Suppressor 1 Inhibits Gene Expression by Targeting Nuclear Factor-κB Activity , 2005 .
[8] Joseph C. Shope,et al. Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells. , 2005, Cancer research.
[9] Josephine C. Adams,et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] J. Workman,et al. Breast Cancer Metastasis Suppressor 1 (BRMS1) Forms Complexes with Retinoblastoma-binding Protein 1 (RBP1) and the mSin3 Histone Deacetylase Complex and Represses Transcription* , 2004, Journal of Biological Chemistry.
[11] D. Welch,et al. Breast cancer metastasis suppressor 1: Update , 2004, Clinical & Experimental Metastasis.
[12] D. Welch,et al. Metastasis suppressor pathways--an evolving paradigm. , 2003, Cancer letters.
[13] C. Osborne,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Steeg,et al. Metastasis suppressor genes: basic biology and potential clinical use. , 2003, Clinical breast cancer.
[15] K. Broman,et al. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. , 2001, Cancer research.
[16] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Holli,et al. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. , 2001, European journal of cancer.
[18] C. Rinker-Schaeffer,et al. Metastasis-suppressor genes: a review and perspective on an emerging field. , 2000, Journal of the National Cancer Institute.
[19] D. Welch,et al. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. , 2000, Cancer research.
[20] G. Hortobagyi,et al. Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer. , 1998, The oncologist.
[21] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.